JPMorgan and UBS Raise PT for Teva Pharmaceutical (TEVA)

Group 1 - Teva Pharmaceutical Industries Ltd. (NYSE:TEVA) is recognized as one of the 11 undervalued stocks to consider buying according to analysts [1] - JPMorgan raised its price target for Teva from $23 to $26 while maintaining an Overweight rating, anticipating no surprises in the upcoming Q3 earnings [1] - UBS also increased its price target for Teva from $23 to $26, keeping a Buy rating [2] Group 2 - UBS raised its sales forecast for Teva for 2030 from $6.3 billion to $6.6 billion, factoring in potential revenue from the Dual-Action Asthma Rescue Inhaler expected to launch in 2028 [3] - The anticipated Dual-Action Asthma Rescue Inhaler is expected to achieve adjusted peak sales of $700 million by 2032 [3] - Teva is an Israeli multinational pharmaceutical company focusing on innovative biopharmaceuticals and a leading generics business [3]